Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients.
A tiny silk sticker that visibly shows vital health signals, read by an AI system, could change how we care for the tiniest patients
Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women’s health, has announced it has received Health Research Authority (HRA) and Research Ethics Committee (REC) approval for its 500-patient clinical observational study, PEMP (Predicting Endometriosis Mechanisms and Populations).
Spotlight Medical, a Paris-based oncology diagnostics company, has announced that myStage Dx has received CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746).
A group of researchers from the Technion and the United States reports a breakthrough in MRI scanning in a paper published in Nature Communications.
Three commercially available radiology AI systems have shown the potential to flag early signs of breast cancer up to six years before a diagnosis, according to a study published in Radiology.
The regulatory clearance covers the t:slim X2 and Tandem Mobi insulin pumps with Control-IQ+ technology.
Researchers used an open-source AI model called Mirai, which was developed by the study’s senior author, UC Berkeley data scientist Adam Yala, Ph.D.
Researchers at Lund University have developed a blood test capable of detecting signs of breast cancer recurrence long before recurrence becomes visible on imaging or causes symptoms.
An international research team led by the Medical University of Vienna has now identified a previously underestimated mechanism by which breast tumors evade the immune system.